US6025154A
(en)
|
1995-06-06 |
2000-02-15 |
Human Genome Sciences, Inc. |
Polynucleotides encoding human G-protein chemokine receptor HDGNR10
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6673341B2
(en)
|
1998-07-06 |
2004-01-06 |
Beth Israel Deaconness Medical Center |
Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis
|
CN1355882A
(zh)
*
|
1999-04-09 |
2002-06-26 |
韩美药品工业株式会社 |
定量转化生长因子-β1的方法以及通过使用该方法检测癌症的方法
|
EP1486560A3
(de)
*
|
1999-04-30 |
2005-02-09 |
Cambridge Antibody Technology LTD |
Antikörper und Antikörperfragmente mit Spezifizität für TGF beta 1
|
US6492497B1
(en)
*
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
WO2001027621A2
(en)
*
|
1999-10-07 |
2001-04-19 |
Pharmacia Corporation |
Competitive inhibition elisa for antibody detection
|
SE9903895D0
(sv)
*
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
NZ522700A
(en)
|
2000-06-16 |
2006-02-24 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
JP4434580B2
(ja)
|
2000-11-28 |
2010-03-17 |
メディミューン,エルエルシー |
予防及び治療のために抗rsv抗体を投与/処方する方法
|
CA2430257A1
(en)
*
|
2000-11-28 |
2002-06-06 |
Amgen, Inc. |
Transforming growth factor-beta-related molecules and uses thereof
|
JP2005503116A
(ja)
*
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10
|
US7175988B2
(en)
|
2001-02-09 |
2007-02-13 |
Human Genome Sciences, Inc. |
Human G-protein Chemokine Receptor (CCR5) HDGNR10
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
NZ529359A
(en)
|
2001-05-25 |
2007-04-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
|
US7393934B2
(en)
|
2001-12-21 |
2008-07-01 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
DE10210427A1
(de)
|
2002-03-09 |
2003-10-09 |
Hans Konrad Mueller-Hermelink |
Humaner monoklonaler Antikörper
|
EP1499352A4
(de)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
Rekombinante anti-interleukin-9-antikörper
|
EP1531848A4
(de)
|
2002-06-10 |
2007-03-28 |
Vaccinex Inc |
Differential exprimiertes gen bei brust- und blasenkrebs und kodierte polypeptide
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
AU2003249533A1
(en)
|
2002-07-04 |
2004-01-23 |
Oncomab Gmbh |
Neoplasm specific antibodies and uses thereof
|
RS20050300A
(en)
|
2002-10-16 |
2007-08-03 |
Euro-Celtique S.A., |
Antibodies that bind cell-associated ca 125/0772p and methods of use thereof
|
GB0224436D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Univ Cambridge Tech |
Polypetides methods and means
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
DE10311248A1
(de)
|
2003-03-14 |
2004-09-30 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
US20070172446A1
(en)
|
2003-05-16 |
2007-07-26 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
EP1646655A2
(de)
*
|
2003-07-09 |
2006-04-19 |
Eli Lilly And Company |
Tgf-beta1 liganden
|
CA2532250A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases
|
MXPA06000974A
(es)
|
2003-07-25 |
2006-08-31 |
Amgen Inc |
Antagonistas y agonistas de ldcam y metodos para su uso.
|
EP1668111A4
(de)
|
2003-08-08 |
2008-07-02 |
Genenews Inc |
Osteoarthritis-biomarker und verwendungen davon
|
DE10353175A1
(de)
|
2003-11-14 |
2005-06-16 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper mit fettsenkender Wirkung
|
EP1531162A1
(de)
|
2003-11-14 |
2005-05-18 |
Heinz Vollmers |
Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
|
EP1723178A4
(de)
|
2004-03-12 |
2007-12-12 |
Human Genome Sciences Inc |
Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
CN101495498B
(zh)
|
2005-02-07 |
2013-09-18 |
基因信息公司 |
轻度骨关节炎生物标志物及其用途
|
ES2711213T3
(es)
|
2005-02-08 |
2019-04-30 |
Genzyme Corp |
Anticuerpos de TGFbeta
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
EP1858545A2
(de)
|
2005-03-04 |
2007-11-28 |
Curedm Inc. |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
|
EP1874818B1
(de)
|
2005-04-22 |
2011-04-13 |
Eli Lilly And Company |
Tgf-beta-1-spezifische antikörper
|
EP2221316A1
(de)
|
2005-05-05 |
2010-08-25 |
Duke University |
CD19-Antikörper-Therapie für Autoimmunerkrankungen
|
US7393919B2
(en)
|
2005-05-25 |
2008-07-01 |
Cure Dm, Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
US8239136B2
(en)
|
2005-10-21 |
2012-08-07 |
Genenews Inc. |
Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
|
EP1948675B1
(de)
|
2005-10-25 |
2014-07-30 |
The Johns Hopkins University |
Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
|
EP1999148B8
(de)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanisierte anti-cd22-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
|
EP2230252A1
(de)
|
2006-03-13 |
2010-09-22 |
The Johns Hopkins University |
Erhöhung der endothelialen Thromboresistenz
|
EP2037961B1
(de)
|
2006-06-14 |
2015-11-11 |
MacroGenics, Inc. |
Verfahren zur behandlung von autoimmunerkrankungen anhand von monoklonalen antikörpern mit verminderter toxizität
|
MY162024A
(en)
|
2006-08-28 |
2017-05-31 |
La Jolla Inst Allergy & Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
EP3254696A1
(de)
|
2006-10-03 |
2017-12-13 |
Genzyme Corporation |
Verwendung von tgf-beta-antagonisten zur behandlung von kleinkindern mit dem risiko des ausbruchs von bronchopulmonaler dysplasie
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
EP2068923A4
(de)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
Antikörper mit verminderten deamidierungsprofilen
|
EP2703011A3
(de)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
NZ741494A
(en)
|
2007-05-14 |
2022-11-25 |
Kyowa Kirin Co Ltd |
Methods of reducing eosinophil levels
|
KR20100080519A
(ko)
|
2007-08-30 |
2010-07-08 |
큐어디엠 인코포레이티드 |
프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
|
WO2009061818A1
(en)
|
2007-11-05 |
2009-05-14 |
Medimmune, Llc |
Methods of treating scleroderma
|
EP2225275A4
(de)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
Proteinformulierung
|
US20110033378A1
(en)
|
2008-01-18 |
2011-02-10 |
Medlmmune, Llc. |
Cysteine Engineered Antibodies For Site-Specific Conjugation
|
JP5608100B2
(ja)
|
2008-02-08 |
2014-10-15 |
メディミューン,エルエルシー |
低下したFcリガンド親和性を有する抗IFNAR1抗体
|
CN103408664B
(zh)
|
2008-10-31 |
2015-11-25 |
东丽株式会社 |
抗人cxcl1单克隆抗体或其片段
|
US20110293605A1
(en)
|
2008-11-12 |
2011-12-01 |
Hasige Sathish |
Antibody formulation
|
WO2010082134A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
EP2464664B1
(de)
|
2009-08-13 |
2015-09-23 |
Crucell Holland B.V. |
Antikörper gegen humanes respiratorisches syncytialvirus und anwendungsverfahren
|
EP2496243A2
(de)
|
2009-11-04 |
2012-09-12 |
Erasmus University Medical Center Rotterdam |
Neuartige verbindungen zur modulierung der gefässneubildung und behandlungsverfahren mit diesen verbindungen
|
HUE027831T2
(en)
|
2010-03-12 |
2016-11-28 |
Genzyme Corp |
Combination therapy for breast cancer
|
EP2591000B1
(de)
|
2010-07-09 |
2017-05-17 |
Janssen Vaccines & Prevention B.V. |
Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
|
CA2823154A1
(en)
|
2010-12-27 |
2012-07-05 |
Lsip, Llc |
Ips cells and method for generating same
|
EP2668210B1
(de)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und ihre verwendungen
|
WO2013014262A1
(en)
|
2011-07-27 |
2013-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating myhre syndrome
|
MX2014004994A
(es)
|
2011-10-26 |
2014-08-27 |
Seattle Children S Res Inst |
Cisteamina en el tratamiento de enfermedad fibrotica.
|
WO2013078286A1
(en)
|
2011-11-22 |
2013-05-30 |
Cornell University |
Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
EP2799537B1
(de)
|
2011-12-28 |
2021-09-22 |
Kyoto Prefectural Public University Corporation |
Normalisierung der züchtung von hornhautendothelzellen
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
DK2953634T3
(da)
|
2013-02-07 |
2021-08-30 |
Massachusetts Gen Hospital |
Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
TWI664979B
(zh)
*
|
2013-03-11 |
2019-07-11 |
健臻公司 |
經生物工程之抗-TGF-β抗體及抗原結合片段
|
NZ713219A
(en)
|
2013-03-14 |
2017-04-28 |
Massachusetts Inst Technology |
Compositions and methods for epithelial stem cell expansion and culture
|
EP3003390B1
(de)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54-antikörper und verwendungen davon
|
AU2014278833A1
(en)
|
2013-06-13 |
2016-01-07 |
Fast Forward Pharmaceuticals B.V. |
CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
RU2699289C2
(ru)
|
2013-08-26 |
2019-09-04 |
Байонтек Рисерч Энд Дивелопмент, Инк. |
НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА
|
CA3189270A1
(en)
|
2013-10-01 |
2015-04-09 |
Toray Industries, Inc. |
Method for detecting pancreatic tumor, antibodies, and kit for the detection of pancreatic tumor
|
EP3064222B1
(de)
|
2013-10-31 |
2020-10-21 |
Kyoto Prefectural Public University Corporation |
Therapeutikum enthaltend einen tgf-beta signalblocker für erkrankungen im zusammenhang mit endoplasmatischem retikulumszelltod im hornhautendothel
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
AU2015271685B2
(en)
|
2014-06-04 |
2021-02-18 |
Biontech Research And Development, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
CN107073042A
(zh)
|
2014-09-03 |
2017-08-18 |
布里格海姆妇女医院公司 |
用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
|
US9982061B2
(en)
|
2014-10-01 |
2018-05-29 |
Medimmune Limited |
Antibodies to ticagrelor and methods of use
|
US10766959B2
(en)
|
2014-12-11 |
2020-09-08 |
Pierre Fabre Medicament |
Anti-C10ORF54 antibodies and uses thereof
|
EP3237450B1
(de)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anti-mertk-antikörper und verwendungen davon
|
EP3252474B1
(de)
|
2015-01-26 |
2020-10-21 |
Toray Industries, Inc. |
Verfahren und kit zur detektion von gallengangkrebs
|
EP3267197B1
(de)
|
2015-03-02 |
2020-09-16 |
Toray Industries, Inc. |
Pankreasfehlfunktionsnachweisverfahren und nachweiskit
|
CN114504652A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
KR20180015650A
(ko)
|
2015-05-07 |
2018-02-13 |
아게누스 인코포레이티드 |
항-ox40 항체 및 이의 사용 방법
|
CN115043943A
(zh)
*
|
2015-05-15 |
2022-09-13 |
综合医院公司 |
拮抗性抗肿瘤坏死因子受体超家族抗体
|
US10882903B2
(en)
|
2015-05-18 |
2021-01-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods and compositions for treating an alphavirus infection
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
MA48579A
(fr)
|
2015-09-01 |
2020-03-18 |
Agenus Inc |
Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
|
EP3400286A1
(de)
|
2016-01-08 |
2018-11-14 |
Massachusetts Institute Of Technology |
Herstellung von differenzierten enteroendokrinen zellen und insulinproduzierenden zellen
|
WO2017141208A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Novartis Ag |
Tgfbeta 2 antibodies
|
US10201540B2
(en)
|
2016-03-02 |
2019-02-12 |
Frequency Therapeutics, Inc. |
Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
|
US10213511B2
(en)
|
2016-03-02 |
2019-02-26 |
Frequency Therapeutics, Inc. |
Thermoreversible compositions for administration of therapeutic agents
|
US11260130B2
(en)
|
2016-03-02 |
2022-03-01 |
Frequency Therapeutics, Inc. |
Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
|
CN109071646A
(zh)
|
2016-03-11 |
2018-12-21 |
供石公司 |
TGFβ1-结合免疫球蛋白及其用途
|
KR102410778B1
(ko)
|
2016-05-13 |
2022-06-21 |
더 제너럴 하스피탈 코포레이션 |
길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
|
WO2017201036A1
(en)
|
2016-05-17 |
2017-11-23 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
SG11201810023QA
(en)
|
2016-05-27 |
2018-12-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
MA45602A
(fr)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
CN117586403A
(zh)
|
2016-10-11 |
2024-02-23 |
艾吉纳斯公司 |
抗lag-3抗体及其使用方法
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
EP3535294A4
(de)
|
2016-11-07 |
2020-09-30 |
Neuracle Science Co., Ltd. |
Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
|
EA201991383A1
(ru)
|
2016-12-07 |
2019-12-30 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
MA50948A
(fr)
|
2016-12-07 |
2020-10-14 |
Agenus Inc |
Anticorps et procédés d'utilisation de ceux-ci
|
KR20190104359A
(ko)
|
2016-12-30 |
2019-09-09 |
프리퀀시 테라퓨틱스, 인크. |
줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법
|
TWI787230B
(zh)
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
TWI788321B
(zh)
|
2017-01-20 |
2023-01-01 |
美商健臻公司 |
骨靶向抗體
|
EP3609921A2
(de)
|
2017-04-13 |
2020-02-19 |
Agenus Inc. |
Anti-cd137-antikörper und verfahren zur verwendung davon
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
EP3618863B1
(de)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antikörper und deren verwendung
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
JP7437301B2
(ja)
|
2017-08-25 |
2024-02-22 |
ファイヴ プライム セラピューティクス インク |
B7-h4抗体及びその使用方法
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
CA3080103A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
JP2021502066A
(ja)
|
2017-11-06 |
2021-01-28 |
ジェネンテック, インコーポレイテッド |
がんの診断及び療法
|
JP7165193B2
(ja)
|
2017-11-27 |
2022-11-02 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ヒト組織因子を標的とするヒト化抗体
|
EA202091810A1
(ru)
|
2018-03-02 |
2021-01-29 |
Файв Прайм Терапьютикс, Инк. |
Антитела к b7-h4 и способы их применения
|
KR20200122409A
(ko)
|
2018-05-10 |
2020-10-27 |
주식회사 뉴라클사이언스 |
서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
|
EP3814376A4
(de)
|
2018-06-26 |
2022-07-06 |
Mor Research Applications Ltd. |
Transthyretinantikörper und verwendungen davon
|
AU2019306165A1
(en)
|
2018-07-20 |
2021-02-25 |
Pierre Fabre Medicament |
Receptor for vista
|
JP2021533788A
(ja)
|
2018-08-17 |
2021-12-09 |
フリークエンシー セラピューティクス インコーポレイテッド |
Jag−1を上方制御することにより有毛細胞を生成するための組成物及び方法
|
US11617745B2
(en)
|
2018-08-17 |
2023-04-04 |
Frequency Therapeutics, Inc. |
Compositions and methods for generating hair cells by downregulating FOXO
|
CN112839957A
(zh)
|
2018-09-28 |
2021-05-25 |
协和麒麟株式会社 |
Il-36抗体及其用途
|
CN112969503A
(zh)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
|
US20220289857A1
(en)
|
2018-12-20 |
2022-09-15 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
CA3130303A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
EP3947737A2
(de)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur vorhersage und vorbeugung von krebs bei patienten mit prämalignen läsionen
|
MX2022001882A
(es)
|
2019-08-12 |
2022-05-30 |
Aptevo Res & Development Llc |
Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
|
BR112022003740A2
(pt)
|
2019-08-30 |
2022-05-31 |
Agenus Inc |
Anticorpos anti-cd96 e métodos de uso dos mesmos
|
EP4025606A1
(de)
|
2019-09-04 |
2022-07-13 |
Y-Biologics Inc. |
Anti-vsig4-antikörper oder antigenbindendes fragment und verwendungen davon
|
CN112852738B
(zh)
*
|
2019-11-27 |
2023-02-28 |
四川省肿瘤医院 |
一种前列腺癌细胞膜片的制备方法
|
KR20220143048A
(ko)
|
2020-02-18 |
2022-10-24 |
알렉터 엘엘씨 |
Pilra 항체 및 이의 사용 방법
|
US20230235073A1
(en)
|
2020-03-06 |
2023-07-27 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
US20210355196A1
(en)
|
2020-05-17 |
2021-11-18 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
EP4182343A2
(de)
|
2020-07-20 |
2023-05-24 |
AstraZeneca UK Limited |
Sars-cov-2-proteine, anti-sars-cov-2-antikörper und verfahren zur verwendung davon
|
US11725052B2
(en)
|
2020-08-18 |
2023-08-15 |
Cephalon Llc |
Anti-PAR-2 antibodies and methods of use thereof
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
MX2023006426A
(es)
|
2020-12-01 |
2023-07-17 |
Aptevo Res & Development Llc |
Antígenos asociados a tumores y proteínas de unión a cd3 y composiciones y métodos relacionados.
|
EP4301786A1
(de)
|
2021-03-03 |
2024-01-10 |
Pierre Fabre Medicament |
Anti-vsig4-antikörper oder antigenbindendes fragment und verwendungen davon
|
JPWO2022202826A1
(de)
|
2021-03-24 |
2022-09-29 |
|
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
IL309934A
(en)
|
2021-07-30 |
2024-03-01 |
Ona Therapeutics S L |
Anti-CD36 antibodies and their use for cancer treatment
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
WO2024077166A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|